Skip to main content
Raju (Radha) Pillai, MD, Pathology, Duarte, CA, City of Hope Comprehensive Cancer Center

RajuK(Radha)PillaiMD

Pathology Duarte, CA

Hematopathology, Molecular Genetics, Anatomic Pathology, Clinical Pathology

Hematopathologist and Director, Pathology Bioinformatics

Dr. Pillai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Pillai's full profile

Already have an account?

Summary

  • I am a board-certified hematopathologist and molecular pathologist.

Education & Training

  • UPMC Medical Education
    UPMC Medical EducationFellowship, Hematopathology, 2010 - 2012
  • UPMC Medical Education
    UPMC Medical EducationFellowship, Molecular Genetic Pathology, 2009 - 2010
  • University of Southern California/LAC+USC Medical Center
    University of Southern California/LAC+USC Medical CenterResidency, Pathology-Anatomic and Clinical, 2005 - 2009
  • Calicut Medical College
    Calicut Medical CollegeClass of 1993

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2008 - 2024
  • PA State Medical License
    PA State Medical License 2009 - 2016
  • American Board of Pathology Pathology - Anatomic/Pathology - Clinical
  • American Board of Pathology Pathology - Molecular Genetic
  • American Board of Pathology Hematopathology

Publications & Presentations

PubMed

Journal Articles

  • ERα-Mediated Cell Cycle Progression Is an Important Requisite for CDK4/6 Inhibitor Response in HR+ Breast Cancer  
    Joanne Mortimer, Laura Kruper, Raju Pillai, George Somlo, Yuan Yuan, Oncotarget

Abstracts/Posters

  • Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma
    Raju Pillai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Hospital Affiliations